CPhI Worldwide, held in Madrid on 13-15 October 2015, was attended by more than 2,500 firms in the pharmaceutical sector and by more than 36,000 professionals from 153 countries.
This is a key event during which Bioiberica celebrated their 40th anniversary and shared their experience and know-how in the identification, isolation and extraction of biomolecules, especially those having high biological and therapeutic value and from tissues of animal origin. The firm presented the Human Health Division’s main products: heparin (the most used anticoagulant and antithrombotic product in the world), pharmaceutical finished products, and active substances for the treatment of osteoarthritis and joint healthcare. Furthermore, they presented the new range of functional lipids, which has shown promising efficacy in several therapeutic areas such as cognitive, dermal or metabolic health.
This is the tenth time that Bioiberica attended this event, which is an excellent platform for strengthening ties with our customers, making new contacts with commercial partners, as well as identifying new business opportunities at the international level. This year, the exhibitors’ area of the CPhI Worldwide covered more than 200,000 square meters and presented information on excipients, ready to use dosages, contract services, packaging and machinery. The 2016 CPhI Worldwide will be hosted in Barcelona.
We participated in CPHI 2023 in Barcelona, where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.
They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs
Join Bioiberica at stand F130 in Geneva, 9-11 May to discover the company’s latest science and insights driving innovation in the nutraceuticals market.